Fortress Biotech Inc
FBIO3.270USD
+0.340+11.60%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
101.39MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Fortress Biotech Inc Unternehmen
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Fortress Biotech Inc Informationen
BörsenkürzelFBIO
Name des UnternehmensFortress Biotech Inc
IPO-datumNov 17, 2011
CEORosenwald (Lindsay A)
Anzahl der mitarbeiter101
WertpapierartOrdinary Share
GeschäftsjahresendeNov 17
Addresse1111 Kane Concourse
StadtBAY HARBOR ISLANDS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33154
Telefon17816524500
Websitehttps://www.fortressbiotech.com/
BörsenkürzelFBIO
IPO-datumNov 17, 2011
CEORosenwald (Lindsay A)
Führungskräfte von Fortress Biotech Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-1567515.00%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
54.76K
+27322.00%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
13.60K
+2711.00%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-1567515.00%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
54.76K
+27322.00%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
13.60K
+2711.00%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Wed, Apr 2
Währung: USDAktualisiert: Wed, Apr 2
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Rosenwald (Lindsay A)
13.25%
Weiss (Michael S)
5.80%
The Vanguard Group, Inc.
3.55%
Summit Financial, LLC
1.43%
Susquehanna International Group, LLP
1.15%
Andere
74.82%
Aktionäre
Aktionäre
Anteil
Rosenwald (Lindsay A)
13.25%
Weiss (Michael S)
5.80%
The Vanguard Group, Inc.
3.55%
Summit Financial, LLC
1.43%
Susquehanna International Group, LLP
1.15%
Andere
74.82%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
20.56%
Investment Advisor
10.15%
Investment Advisor/Hedge Fund
2.69%
Hedge Fund
1.38%
Research Firm
0.51%
Bank and Trust
0.14%
Pension Fund
0.06%
Andere
64.52%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
92
4.96M
26.50%
--
2025Q3
107
4.96M
27.33%
--
2025Q2
114
4.96M
27.45%
+47.82K
2025Q1
116
4.91M
27.75%
-3.29M
2024Q4
121
4.82M
26.63%
+370.47K
2024Q3
123
4.48M
24.67%
+822.95K
2024Q2
130
3.66M
27.39%
+620.10K
2024Q1
155
3.04M
28.91%
-2.56M
2023Q4
162
4.72M
15.96%
+3.18M
2023Q3
164
1.59M
428.37%
-108.10K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rosenwald (Lindsay A)
4.11M
13.25%
-1.57M
-27.60%
Apr 17, 2025
Weiss (Michael S)
1.80M
5.8%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
950.33K
3.06%
+97.41K
+11.42%
Sep 30, 2025
Summit Financial, LLC
444.75K
1.43%
-571.10K
-56.22%
Sep 30, 2025
Susquehanna International Group, LLP
356.18K
1.15%
+310.54K
+680.49%
Sep 30, 2025
Shikiar Asset Management, Inc.
278.47K
0.9%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
244.42K
0.79%
+9.63K
+4.10%
Sep 30, 2025
Northern Trust Investments, Inc.
220.64K
0.71%
+127.41K
+136.67%
Sep 30, 2025
Sculptor Capital Management, Inc
208.90K
0.67%
+208.90K
--
Sep 30, 2025
Kestra Advisory Services, LLC
196.88K
0.63%
-135.12K
-40.70%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
Fidelity Enhanced Small Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
